Skip to main content
logo
Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
14.75
-0.36 (-2.38%)
At close: Jul 17, 2026, 4:00 PM EDT
14.69
-0.06 (-0.41%)
After-hours: Jul 17, 2026, 4:24 PM EDT

Crescent Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-10.84-0.010.081.16
Revenue Growth (YoY)
----86.67%-93.53%-88.59%
Gross Profit
-10.84-0.010.081.16
Selling, General & Admin
29.6625.3918.2519.2119.0917.12
Research & Development
145.36138.0914.2620.0728.3947.49
Other Operating Expenses
--7.53---
Total Operating Expenses
175.02163.4840.0439.2947.4864.61
Operating Income
-163.14-152.63-40.04-39.28-47.4-63.45
Interest Income
4.132.880.942.380.710.02
Interest Expense
-1.07-2.19----
Other Non-Operating Income (Expense)
--3.392.38--
Total Non-Operating Income (Expense)
3.060.694.324.750.710.02
Pretax Income
-160.08-151.94-35.72-34.52-46.69-63.43
Net Income
-162.08-153.94-37.88-36.9-46.69-63.43
Net Income to Common
-162.08-153.94-37.88-36.9-46.69-63.43
Shares Outstanding (Basic)
18101111
Shares Outstanding (Diluted)
18101111
Shares Change (YoY)
2331.49%1515.08%1.79%20.58%2.10%12.54%
EPS (Basic)
-10.91-12.81-59.00-58.00-89.00-123.00
EPS (Diluted)
-10.91-12.81-59.00-58.00-89.00-123.00
Free Cash Flow
-76.43-72.45-6.27-34.9-46.54-57.5
Free Cash Flow Per Share
-4.31-6.96-9.72-55.10-88.60-111.76
Gross Margin
-100.00%-100.00%100.00%100.00%
Operating Margin
--1407.52%--392753.00%-63204.40%-5470.69%
Profit Margin
--1419.61%--368994.00%-62251.70%-5468.98%
FCF Margin
--668.12%--349013.00%-62055.60%-4958.28%
EBITDA
-162.99-152.55-40.04-39.12-47.2-63.18
EBITDA Margin
--1406.75%--391220.00%-62928.20%-5447.87%
EBIT
-163.14-152.63-40.04-39.28-47.4-63.45
EBIT Margin
--1407.52%--392753.00%-63204.40%-5470.69%
SEC Filings: 10-K · 10-Q